Skip to content
Peptigraph home

KPV Benefits: Claims vs What Studies Show

Benefits people claim for KPV, set against what published studies measured, and where no study exists.

Medical review pendingAnti-inflammatory tripeptideUpdated
Strongest evidence
Animal
Human / animal studies
0 / 4
in our evidence file (PubMed search, 11 Oct 2026)
FDA status
Not approved
Off Category 2, 15 Apr 2026

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

KPV claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
InflammationAnimal evidence, 2 of 40 / 6DSS colitis recovery; Survival in MC1R-nonfunctional mice; Colitis incidence (oral KPV)Evidence for inflammation
Gut healthAnimal evidence, 2 of 40 / 2DSS colitis recovery; Survival in MC1R-nonfunctional mice; Colitis incidence (oral KPV)Evidence for gut health
SkinIn vitro evidence, 1 of 40 / 3Keratinocyte viability and IL-1beta; Skin permeation; Cyclic AMP signallingEvidence for skin
AllergiesIn vitro evidence, 1 of 40 / 1Airway epithelial inflammatory signallingEvidence for allergies

Strongest study per claim: Inflammation, Inflammatory bowel diseases 2008, PMID 18092346; Gut health, Inflammatory bowel diseases 2008, PMID 18092346; Skin, Tissue & cell 2025, PMID 40073467.

What the studies measured

KPV outcomes in published studies
OutcomeResultStudy typeSource
DSS colitis recoveryKPV-treated mice recovered earlier and regained more body weight in DSS colitis.Animal · mouse (not a human result)Inflammatory bowel diseases 2008, PMID 18092346
Survival in MC1R-nonfunctional miceKPV treatment rescued all treated MC1R-nonfunctional mice from death during DSS colitis.Animal · mouse (not a human result)Inflammatory bowel diseases 2008, PMID 18092346
Colitis incidence (oral KPV)Oral KPV in drinking water reduced the incidence of DSS- and TNBS-induced colitis in mice and lowered inflammatory cytokine expression.Animal · mouse (plus human intestinal epithelial and T cell lines) (not a human result)Gastroenterology 2008, PMID 18061177
Peritonitis (neutrophil accumulation)KPV reduced inflammatory cell accumulation in mouse peritonitis through a mechanism distinct from other melanocortin peptides.Animal · mouse (not a human result)The Journal of pharmacology and experimental therapeutics 2003, PMID 12750433
FeverThe tripeptide reduced fever in rabbits after central (0.5-2.0 mg) and peripheral (2-200 mg) administration.Animal · rabbit (not a human result)Peptides 1984, PMID 6333677
Keratinocyte viability and IL-1betaKPV at 50 ug/mL restored cell viability and reduced IL-1beta secretion in PM10-exposed keratinocytes.In vitro (not a human result)Tissue & cell 2025, PMID 40073467
Skin permeationKPV did not permeate human skin by passive diffusion alone (below the detection limit of 0.01 ug/mL); microneedles and iontophoresis were needed.In vitro (not a human result)Journal of pharmaceutical sciences 2017, PMID 28343991
Degradation under stressUnder acid, alkali and hydrogen peroxide stress KPV degraded mainly to lys-pro-diketopiperazine.In vitro (not a human result)Biomedical chromatography 2015, PMID 25298219
Airway epithelial inflammatory signallingKPV dose-dependently inhibited NF-kB signalling, MMP-9 activity, and IL8 and eotaxin secretion in cultured airway cells.In vitro (not a human result)International journal of physiology, pathophysiology and pharmacology 2012, PMID 22837805
Cyclic AMP signallingKPV did not raise cyclic AMP in human keratinocytes (mechanism study; no clinical outcome).In vitro (not a human result)The Journal of investigative dermatology 2004, PMID 15102092
Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “(KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab])”: 132 results. PubMed search on 2 Oct 2026 for “(KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (alpha-MSH[tiab] OR melanocortin[tiab] OR colitis[tiab] OR inflammat*[tiab])”: 95 results. PubMed search on 2 Oct 2026 for “(KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab])”: 2 results. PubMed search on 2 Oct 2026 for “(KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (clinical trial[pt] OR randomized[tiab] OR patients[tiab])”: 9 results.

What KPV is, from the studies

KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone.[6]

The gut-health claim: mouse colitis studies

In mice with DSS colitis, KPV led to earlier recovery and significantly stronger regain of body weight (animal study).[1]

In melanocortin-1-receptor-deficient mice, KPV rescued every treated animal from death during DSS colitis (animal study).[1]

Oral KPV in drinking water reduced the incidence of DSS- and TNBS-induced colitis in mice (animal study).[2]

Inflammation, skin and allergy claims: cells and animals only

In mice with crystal-induced peritonitis, systemic KPV significantly reduced the build-up of polymorphonuclear leukocytes in the peritoneal cavity (animal study).[3]

In human HaCaT skin cells exposed to fine dust, KPV restored cell viability and reduced IL-1β secretion (cell study).[5]

In immortalised human bronchial epithelial cells, KPV inhibited NFκB, IL8 and eotaxin secretion in a dose-dependent way, which is the nearest the cached sources come to an allergy-type claim (cell study).[8]

In rabbits made febrile, the KPV tripeptide reduced fever after both central and peripheral administration (animal study).[4]

Claims with no human study

None of the 9 cached KPV abstracts reports a study in living human participants; they are mouse, rabbit, cell-line and ex vivo skin studies, so every benefit above is unconfirmed in people.

Calculated from cached abstracts 18092346, 18061177, 12750433, 22837805, 40073467, 15102092, 6333677, 28343991, 25298219; human participant studies 0; animal only yes. Formula: count of cached abstracts reporting living human participants = 0

A dated PubMed search (2026-10-02) for KPV with clinical-trial terms returned 9 records; none of the cached abstracts behind this page is a KPV trial in people.

Calculated from evidence file web/src/data/evidence/kpv.json; query (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (clinical trial[pt] OR randomized[tiab] OR patients[tiab]); date 2026-10-02; count 9. Formula: count of PubMed records returned by the dated query

Common questions

Is KPV proven to work?

The strongest study we summarise for KPV is animal evidence, among 9 studies. That is not proof it works in people.

What does KPV peptide do?

The cached studies describe an anti-inflammatory tripeptide: in mice it reduced colitis, and the authors of a mouse peritonitis study conclude it acts differently from the core MSH peptides.[3]

Is KPV peptide proven for gut health?

No. The gut evidence is from mouse colitis models, with no human trial in the cached set.

Calculated from mouse colitis studies 2; human trials 0. Formula: cached gut studies in people = 0

More on KPV

Sources

  1. 1Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
  2. 2PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.Gastroenterology · 2008PMID 18061177Accessed 2 Oct 2026
  3. 3Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.The Journal of pharmacology and experimental therapeutics · 2003PMID 12750433Accessed 2 Oct 2026
  4. 4Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit.Peptides · 1984PMID 6333677Accessed 2 Oct 2026
  5. 5Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.Tissue & cell · 2025PMID 40073467Accessed 2 Oct 2026
  6. 6Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.Journal of pharmaceutical sciences · 2017PMID 28343991Accessed 2 Oct 2026
  7. 7Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates.Biomedical chromatography : BMC · 2015PMID 25298219Accessed 2 Oct 2026
  8. 8Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.International journal of physiology, pathophysiology and pharmacology · 2012PMID 22837805Accessed 2 Oct 2026
  9. 9alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.The Journal of investigative dermatology · 2004PMID 15102092Accessed 2 Oct 2026
  10. 10PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) (132 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (alpha-MSH[tiab] OR melanocortin[tiab] OR colitis[tiab] OR inflammat*[tiab]) (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (clinical trial[pt] OR randomized[tiab] OR patients[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026

Found an error? Report a correction.